Loading...

ZIOPHARM Oncology

DB:WEK
Snowflake Description

Flawless balance sheet and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
WEK
DB
$676M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The last earnings update was 49 days ago. More info.


Add to Portfolio Compare Print
  • ZIOPHARM Oncology has significant price volatility in the past 3 months.
WEK Share Price and Events
7 Day Returns
-1.6%
DB:WEK
-2.7%
DE Biotechs
1.5%
DE Market
1 Year Returns
4.4%
DB:WEK
-10.6%
DE Biotechs
-6.2%
DE Market
WEK Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
ZIOPHARM Oncology (WEK) -1.6% -3.8% 98.6% 4.4% -47.6% 55.7%
DE Biotechs -2.7% 3.8% -8.5% -10.6% 47.4% 10.3%
DE Market 1.5% 6% 8.5% -6.2% 10.7% 15.3%
1 Year Return vs Industry and Market
  • WEK outperformed the Biotechs industry which returned -10.6% over the past year.
  • WEK outperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
WEK
Industry
5yr Volatility vs Market
Related Companies

Value

 Is ZIOPHARM Oncology undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for ZIOPHARM Oncology. This is due to cash flow or dividend data being unavailable. The share price is €3.655.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for ZIOPHARM Oncology's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are ZIOPHARM Oncology's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:WEK PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $0.96
NasdaqCM:ZIOP Share Price ** NasdaqCM (2019-04-23) in USD $4.16
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.6x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of ZIOPHARM Oncology.

DB:WEK PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:ZIOP Share Price ÷ EPS (both in USD)

= 4.16 ÷ 0.96

4.35x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ZIOPHARM Oncology is good value based on earnings compared to the Europe Biotechs industry average.
  • ZIOPHARM Oncology is good value based on earnings compared to the Germany market.
Price based on expected Growth
Does ZIOPHARM Oncology's expected growth come at a high price?
Raw Data
DB:WEK PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 4.35x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
-38.7%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

DB:WEK PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 4.35x ÷ -38.7%

-0.11x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ZIOPHARM Oncology earnings are not expected to grow next year, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on ZIOPHARM Oncology's assets?
Raw Data
DB:WEK PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.53
NasdaqCM:ZIOP Share Price * NasdaqCM (2019-04-23) in USD $4.16
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:WEK PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:ZIOP Share Price ÷ Book Value per Share (both in USD)

= 4.16 ÷ 0.53

7.8x

* Primary Listing of ZIOPHARM Oncology.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ZIOPHARM Oncology is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess ZIOPHARM Oncology's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. ZIOPHARM Oncology has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is ZIOPHARM Oncology expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-38.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is ZIOPHARM Oncology expected to grow at an attractive rate?
  • ZIOPHARM Oncology's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 0.2%.
Growth vs Market Checks
  • ZIOPHARM Oncology's earnings are expected to decrease over the next 1-3 years, this is below the Germany market average.
  • ZIOPHARM Oncology's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:WEK Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:WEK Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts -38.7%
DB:WEK Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 75.1%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:WEK Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:WEK Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 103 -32 2
2022-12-31 4 -72 2
2021-12-31 2 -64 4
2020-12-31 1 -54 -58 5
2019-12-31 1 -48 -57 5
DB:WEK Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 0 -49 137
2018-09-30 2 -50 -76
2018-06-30 3 -54 -75
2018-03-31 5 -59 -75
2017-12-31 6 -55 -73
2017-09-30 6 -56 -70
2017-06-30 6 -57 -67
2017-03-31 6 -57 -180
2016-12-31 7 -58 -172
2016-09-30 7 -69 -167
2016-06-30 7 -10 -171
2016-03-31 6 -6 -54

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • ZIOPHARM Oncology's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
  • ZIOPHARM Oncology's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:WEK Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from ZIOPHARM Oncology Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:WEK Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.19 0.03 -0.41 2.00
2022-12-31 -0.39 -0.39 -0.39 2.00
2021-12-31 -0.35 -0.25 -0.51 4.00
2020-12-31 -0.33 -0.28 -0.42 4.00
2019-12-31 -0.32 -0.26 -0.35 5.00
DB:WEK Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 0.96
2018-09-30 -0.54
2018-06-30 -0.53
2018-03-31 -0.54
2017-12-31 -0.53
2017-09-30 -0.52
2017-06-30 -0.51
2017-03-31 -1.38
2016-12-31 -1.32
2016-09-30 -1.28
2016-06-30 -1.31
2016-03-31 -0.42

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if ZIOPHARM Oncology will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess ZIOPHARM Oncology's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
ZIOPHARM Oncology has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has ZIOPHARM Oncology performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare ZIOPHARM Oncology's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • ZIOPHARM Oncology's year on year earnings growth rate has been positive over the past 5 years.
  • ZIOPHARM Oncology has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • ZIOPHARM Oncology has become profitable in the last year making it difficult to compare the Europe Biotechs industry average.
Earnings and Revenue History
ZIOPHARM Oncology's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from ZIOPHARM Oncology Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:WEK Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.15 137.25 19.92
2018-09-30 1.74 -75.56 19.21
2018-06-30 3.34 -74.51 18.47
2018-03-31 4.94 -74.74 17.36
2017-12-31 6.39 -73.26 14.80
2017-09-30 6.39 -69.75 14.27
2017-06-30 6.39 -66.59 14.23
2017-03-31 6.49 -180.06 14.16
2016-12-31 6.86 -172.42 14.38
2016-09-30 7.18 -167.14 14.32
2016-06-30 7.45 -170.87 13.85
2016-03-31 6.03 -53.88 17.21
2015-12-31 4.33 -120.09 17.65
2015-09-30 2.75 -121.01 17.24
2015-06-30 1.52 -108.94 17.02
2015-03-31 1.45 -100.30 12.97
2014-12-31 1.37 -31.78 12.17
2014-09-30 1.23 -30.28 12.15
2014-06-30 0.80 -40.90 12.37
2014-03-31 0.80 -54.02 13.06
2013-12-31 0.80 -57.11 14.29
2013-09-30 0.80 -78.43 15.52
2013-06-30 0.80 -79.54 16.87
2013-03-31 0.80 -84.46 18.05
2012-12-31 0.80 -96.13 18.22
2012-09-30 0.80 -79.15 18.13 -26.93
2012-06-30 0.80 -62.13 17.46 -15.57

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if ZIOPHARM Oncology has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • ZIOPHARM Oncology used its assets more efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • It is difficult to establish if ZIOPHARM Oncology improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess ZIOPHARM Oncology's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
ZIOPHARM Oncology has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is ZIOPHARM Oncology's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up ZIOPHARM Oncology's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • ZIOPHARM Oncology is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • ZIOPHARM Oncology's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of ZIOPHARM Oncology's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • ZIOPHARM Oncology has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from ZIOPHARM Oncology Company Filings, last reported 3 months ago.

DB:WEK Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 85.56 0.00 61.73
2018-09-30 4.02 0.00 31.73
2018-06-30 15.19 0.00 40.40
2018-03-31 25.89 0.00 51.11
2017-12-31 47.19 0.00 70.95
2017-09-30 59.27 0.00 84.41
2017-06-30 69.96 0.00 97.19
2017-03-31 34.54 0.00 66.45
2016-12-31 48.02 0.00 81.05
2016-09-30 57.40 0.00 94.68
2016-06-30 67.06 0.00 109.00
2016-03-31 77.81 0.00 124.85
2015-12-31 87.37 0.00 140.72
2015-09-30 93.84 0.00 163.84
2015-06-30 110.44 0.00 118.55
2015-03-31 120.60 0.00 129.68
2014-12-31 33.84 0.00 42.80
2014-09-30 36.48 0.00 46.12
2014-06-30 37.72 0.00 53.00
2014-03-31 41.73 0.00 60.39
2013-12-31 49.38 0.00 68.20
2013-09-30 3.63 0.00 23.63
2013-06-30 19.33 0.00 38.93
2013-03-31 37.89 0.00 55.66
2012-12-31 48.45 0.00 73.31
2012-09-30 59.03 0.00 95.33
2012-06-30 75.64 0.00 110.39
  • ZIOPHARM Oncology has no debt.
  • ZIOPHARM Oncology has not taken on any debt in the past 5 years.
  • ZIOPHARM Oncology has no debt, it does not need to be covered by operating cash flow.
  • ZIOPHARM Oncology has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess ZIOPHARM Oncology's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. ZIOPHARM Oncology has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is ZIOPHARM Oncology's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from ZIOPHARM Oncology dividends.
If you bought €2,000 of ZIOPHARM Oncology shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate ZIOPHARM Oncology's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate ZIOPHARM Oncology's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:WEK Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:WEK Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as ZIOPHARM Oncology has not reported any payouts.
  • Unable to verify if ZIOPHARM Oncology's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of ZIOPHARM Oncology's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as ZIOPHARM Oncology has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess ZIOPHARM Oncology's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can ZIOPHARM Oncology afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. ZIOPHARM Oncology has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of ZIOPHARM Oncology's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Laurence James Cooper
COMPENSATION $2,594,244
AGE 53
TENURE AS CEO 3.9 years
CEO Bio

Dr. Laurence James Neil Cooper, M.D., Ph.D., has been a Director of Ziopharm Oncology, Inc since October 15, 2018. Dr. Cooper has been the Chief Executive Officer of ZIOPHARM Oncology, Inc. since May 5, 2015 and served as its President until December 13, 2018. Dr. Cooper joined The University of Texas MD Anderson Cancer Center in 2006, where his appointments include tenured professor, Pediatrics and Immunology; Section Chief, Cell Therapy, Children's Cancer Hospital; and Associate Director, Center for Cancer Immunology Research. Dr. Cooper has received numerous awards and honors and in addition to numerous other professional appointments, he has authored more than 140 journal articles, book chapters and abstracts. Dr. Cooper obtained his B.A. at Kenyon College in Gambier, Ohio. Dr. Cooper obtained his M.D. and Ph.D. degrees at Case Western Reserve University in Cleveland and then training in Pediatric Oncology and Bone Marrow Transplantation at the Fred Hutchinson Cancer Research Center in Seattle.

CEO Compensation
  • Laurence James's compensation has increased in line with ZIOPHARM Oncology recently becoming profitable.
  • Laurence James's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the ZIOPHARM Oncology management team in years:

1.4
Average Tenure
51
Average Age
  • The average tenure for the ZIOPHARM Oncology management team is less than 2 years, this suggests a new team.
Management Team

Laurence James Cooper

TITLE
CEO & Director
COMPENSATION
$3M
AGE
53
TENURE
3.9 yrs

David Mauney

TITLE
President
COMPENSATION
$2M
AGE
49
TENURE
0.3 yrs

Kevin Lafond

TITLE
Senior VP of Finance
COMPENSATION
$581K
AGE
62
TENURE
5.8 yrs

Lynn Ferrucci

TITLE
Executive VP of HR

David Connolly

TITLE
Vice President of Corporate Communications & Investor Relations
TENURE
2.3 yrs

Rob Hadfield

TITLE
Executive VP
AGE
40

Jill Buck

TITLE
Executive Vice President of GM Gene Therapy
TENURE
0.5 yrs

Ellee De Groot

TITLE
Executive Vice President of GM Cell Therapy
TENURE
0.1 yrs
Board of Directors Tenure

Average tenure and age of the ZIOPHARM Oncology board of directors in years:

6.5
Average Tenure
61
Average Age
  • The tenure for the ZIOPHARM Oncology board of directors is about average.
Board of Directors

Laurence James Cooper

TITLE
CEO & Director
COMPENSATION
$3M
AGE
53
TENURE
0.5 yrs

Jim Cannon

TITLE
Director
COMPENSATION
$129K
AGE
79
TENURE
13.6 yrs

Scott Tarriff

TITLE
Lead Director
COMPENSATION
$128K
AGE
58
TENURE
0.7 yrs

James Armitage

TITLE
Member of Scientific/Medical Advisory Board
AGE
71

Joseph Bertino

TITLE
Member of Scientific/Medical Advisory Board

George Demetri

TITLE
Member of Scientific/Medical Advisory Board
AGE
61

Lawrence Einhorn

TITLE
Member of Scientific/Medical Advisory Board

Alan Houghton

TITLE
Member of Scientific/Medical Advisory Board

Alberto Pappo

TITLE
Member of Scientific/Medical Advisory Board

John Smyth

TITLE
Member of Scientific/Medical Advisory Board
TENURE
12.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
12. Dec 18 Sell Randal Kirk Individual 28. Nov 18 11. Dec 18 -1,797,230 €2.89 €-5,199,220
X
Management checks
We assess ZIOPHARM Oncology's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. ZIOPHARM Oncology has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient’s immune system to attack cancer cells. Its lead gene therapy product candidate is Ad-RTS-hIL-12 plus veledimex, which is in Phase I clinical trial, to treat patients with recurrent glioblastoma and breast cancer. The company is also developing chimeric antigen receptor (CAR) T-cell and T-cell receptor T-cell therapies. ZIOPHARM Oncology, Inc. has license agreement with Precigen, Inc. and MD Anderson Cancer Center; research and development agreement with the National Cancer Institute, and Ares Trading S.A. The company is headquartered in Boston, Massachusetts.

Details
Name: ZIOPHARM Oncology, Inc.
WEK
Exchange: DB
Founded:
$602,851,835
161,612,424
Website: http://www.ziopharm.com
Address: ZIOPHARM Oncology, Inc.
Parris Building 34,
Navy Yard Plaza,
Boston,
Massachusetts, 02129,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM ZIOP Common Stock Nasdaq Capital Market US USD 16. Sep 2005
DB WEK Common Stock Deutsche Boerse AG DE EUR 16. Sep 2005
Number of employees
Current staff
Staff numbers
48
ZIOPHARM Oncology employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/23 21:04
End of day share price update: 2019/04/23 00:00
Last estimates confirmation: 2019/04/04
Last earnings filing: 2019/03/05
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.